Table 2 Comparisons of the outcomes between PMX-HP and control group in the J-DPC studies and some large-scale studies including RCTs
| Â | Length of ICU/R stay (days)/HP stay rate at day 28(%) | MV-free days | NAD-free days/increasing of BP | CHDF-free days | 28-day outcome (%) |
|---|---|---|---|---|---|
Iwagami et al. [8] | NA | NA | NA | NA | (Mortality) 40.2 vs 46 OR 0.76 p = 0.003 |
Fujimori et al. [11] | NA | 20 (1–28) vs 14 (0–28) p < 0.0001 | 24 (11–26) vs 22 (0–25) p < 0.0001 | 24 (9–28) vs 22 (0–28) p < 0.0001 | (Survival rate) 77.9 vs 71.1 OR 1.433 p < 0.0001 |
Fujimori et al. [10] | 9 (5–13) vs 11 (6–13), p = 0.016/81.6 vs 3.4% HR 1.083 | NA | NA | NA | (Survival rate) 69.5 vs 65.4 HR 0.905 p < 0.0001 |
Fujimori et al. [12] | NA | 16 (0–23) vs 12 (0–22) p = 0.0061 | 24 (15-26) vs 22(0-26) p = 0.0005 | 23 (8–25) vs 21 (0–24) p = 0.0034 | (Mortality) 18.6 vs 27.4 p = 0.0008 |
Dellinger, R. P. et al. [13] | /NS | mean (SD) 12.7 (10.9) vs 9.8 (10.0) p = 0.02 | mean (SD) 8.1 (16.0) vs 3.9 (14.1), p = 0.02/ | NS | NS |
Klein, D. J. et al. [14] | /NS | 20 (0.5–23.5) vs 6 (0–20) p = 0.004 | /8 (−0.5–19.5) vs 4 (−4.0–11) p < 0.05 | NS | (Mortality) 26.1 vs 36.8, OR 0.52, p = 0.047 |
Nakamura, Y. et al. [16] | 14 (0–22) vs 18 (0–22) p < 0.045/ | NA | NA | NA | (HP mortality) 32.8 vs 41.2 OR 0.681 p = 0.042 |